These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27225456)

  • 1. Advances in novel influenza vaccines: a patent review.
    Song JM
    J Microbiol; 2016 Jun; 54(6):403-12. PubMed ID: 27225456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Achieving clinical equality in an influenza pandemic: patent realities.
    Kane EM
    Seton Hall Law Rev; 2009; 39(4):1137-72. PubMed ID: 20718133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus.
    Rudenko L; Isakova-Sivak I
    Expert Rev Vaccines; 2015 Mar; 14(3):395-412. PubMed ID: 25555687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines for pandemic influenza.
    Luke CJ; Subbarao K
    Emerg Infect Dis; 2006 Jan; 12(1):66-72. PubMed ID: 16494720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NEW technologies for meeting the global demand for pandemic influenza vaccines.
    Fedson DS
    Biologicals; 2008 Nov; 36(6):346-9. PubMed ID: 18715803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines in development against avian influenza.
    Cox MM
    Minerva Med; 2007 Apr; 98(2):145-53. PubMed ID: 17519856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The threat of avian influenza A (H5N1). Part IV: Development of vaccines.
    Cinatl J; Michaelis M; Doerr HW
    Med Microbiol Immunol; 2007 Dec; 196(4):213-25. PubMed ID: 17541633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pandemic H5N1 influenza vaccine development: an update.
    El Sahly HM; Keitel WA
    Expert Rev Vaccines; 2008 Mar; 7(2):241-7. PubMed ID: 18324892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
    Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
    J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection.
    Jones T
    Curr Opin Mol Ther; 2009 Jun; 11(3):337-45. PubMed ID: 19479667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Live attenuated vaccines for pandemic influenza.
    Chen GL; Subbarao K
    Curr Top Microbiol Immunol; 2009; 333():109-32. PubMed ID: 19768402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA-based influenza vaccines as immunoprophylactic agents toward universality.
    Zhang H; El Zowalaty ME
    Future Microbiol; 2016; 11(1):153-64. PubMed ID: 26673424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development.
    Barrett PN; Portsmouth D; Ehrlich HJ
    Expert Rev Vaccines; 2013 Apr; 12(4):395-413. PubMed ID: 23560920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, immunogenicity and infectivity of new live attenuated influenza vaccines.
    Isakova-Sivak I; Rudenko L
    Expert Rev Vaccines; 2015; 14(10):1313-29. PubMed ID: 26289975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccines for seasonal and pandemic influenza.
    Nichol KL; Treanor JJ
    J Infect Dis; 2006 Nov; 194 Suppl 2():S111-8. PubMed ID: 17163383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies towards universal pandemic influenza vaccines.
    He F; Leyrer S; Kwang J
    Expert Rev Vaccines; 2016; 15(2):215-25. PubMed ID: 26641724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progress in new vaccine strategies against influenza: a review].
    Liu Z; Jiang T; Qin E; Ran D; Qin C
    Sheng Wu Gong Cheng Xue Bao; 2012 May; 28(5):550-6. PubMed ID: 22916493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for developing vaccines against H5N1 influenza A viruses.
    Horimoto T; Kawaoka Y
    Trends Mol Med; 2006 Nov; 12(11):506-14. PubMed ID: 17011235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preflucel®: a Vero-cell culture-derived trivalent influenza vaccine.
    Chan CY; Tambyah PA
    Expert Rev Vaccines; 2012 Jul; 11(7):759-73. PubMed ID: 22913252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.